vs
Cellectis S.A.（CLLS）与Laird Superfood, Inc.（LSF）财务数据对比。点击上方公司名可切换其他公司
Laird Superfood, Inc.的季度营收约是Cellectis S.A.的1.4倍（$13.3M vs $9.5M），Laird Superfood, Inc.净利率更高（-13.2% vs -265.9%，领先252.7%），Cellectis S.A.同比增速更快（375.0% vs 15.0%）
Cellectis S.A.是一家法国生物制药公司，专注于开发用于癌症免疫治疗的基因编辑嵌合抗原受体T细胞技术，目前在巴黎、纽约以及北卡罗来纳州罗利均设有办公机构，在肿瘤免疫基因编辑疗法领域拥有多年研发积累。
Laird Superfood是一家主营植物基功能性超级食品的企业，产品涵盖精品咖啡奶精、补水混合饮品、营养补充剂、植物能量零食等，面向健康意识较强的消费群体，主要在北美市场通过电商及线下零售渠道销售，主打可持续采购的清洁配方。
CLLS vs LSF — 直观对比
营收规模更大
LSF
是对方的1.4倍
$9.5M
营收增速更快
CLLS
高出359.9%
15.0%
净利率更高
LSF
高出252.7%
-265.9%
损益表 — Q2 FY2024 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.5M | $13.3M |
| 净利润 | $-25.3M | $-1.8M |
| 毛利率 | — | 34.1% |
| 营业利润率 | -181.1% | -13.5% |
| 净利率 | -265.9% | -13.2% |
| 营收同比 | 375.0% | 15.0% |
| 净利润同比 | -51.9% | -341.4% |
| 每股收益（稀释后） | $-0.28 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLLSLSF
| Q4 25 | — | $13.3M | ||
| Q3 25 | — | $12.9M | ||
| Q2 25 | — | $12.0M | ||
| Q1 25 | — | $11.7M | ||
| Q4 24 | — | $11.6M | ||
| Q3 24 | — | $11.8M | ||
| Q2 24 | $9.5M | $10.0M | ||
| Q1 24 | — | $9.9M |
净利润CLLSLSF
| Q4 25 | — | $-1.8M | ||
| Q3 25 | — | $-975.1K | ||
| Q2 25 | — | $-362.2K | ||
| Q1 25 | — | $-156.2K | ||
| Q4 24 | — | $-398.4K | ||
| Q3 24 | — | $-166.1K | ||
| Q2 24 | $-25.3M | $-239.1K | ||
| Q1 24 | — | $-1.0M |
毛利率CLLSLSF
| Q4 25 | — | 34.1% | ||
| Q3 25 | — | 36.5% | ||
| Q2 25 | — | 39.9% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | — | 38.6% | ||
| Q3 24 | — | 43.0% | ||
| Q2 24 | — | 41.8% | ||
| Q1 24 | — | 40.0% |
营业利润率CLLSLSF
| Q4 25 | — | -13.5% | ||
| Q3 25 | — | -7.7% | ||
| Q2 25 | — | -3.3% | ||
| Q1 25 | — | -1.9% | ||
| Q4 24 | — | -4.1% | ||
| Q3 24 | — | -2.3% | ||
| Q2 24 | -181.1% | -3.4% | ||
| Q1 24 | — | -11.0% |
净利率CLLSLSF
| Q4 25 | — | -13.2% | ||
| Q3 25 | — | -7.6% | ||
| Q2 25 | — | -3.0% | ||
| Q1 25 | — | -1.3% | ||
| Q4 24 | — | -3.4% | ||
| Q3 24 | — | -1.4% | ||
| Q2 24 | -265.9% | -2.4% | ||
| Q1 24 | — | -10.3% |
每股收益（稀释后）CLLSLSF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-0.28 | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $149.0M | $5.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $148.6M | $11.5M |
| 总资产 | $407.1M | $19.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLLSLSF
| Q4 25 | — | $5.1M | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $3.9M | ||
| Q1 25 | — | $7.0M | ||
| Q4 24 | — | $8.3M | ||
| Q3 24 | — | $7.9M | ||
| Q2 24 | $149.0M | $7.6M | ||
| Q1 24 | — | $7.1M |
股东权益CLLSLSF
| Q4 25 | — | $11.5M | ||
| Q3 25 | — | $12.8M | ||
| Q2 25 | — | $13.4M | ||
| Q1 25 | — | $13.3M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | — | $13.1M | ||
| Q2 24 | $148.6M | $12.6M | ||
| Q1 24 | — | $12.7M |
总资产CLLSLSF
| Q4 25 | — | $19.2M | ||
| Q3 25 | — | $18.9M | ||
| Q2 25 | — | $20.4M | ||
| Q1 25 | — | $21.5M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | — | $18.8M | ||
| Q2 24 | $407.1M | $18.0M | ||
| Q1 24 | — | $17.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.9M | $68.4K |
| 自由现金流经营现金流 - 资本支出 | $27.6M | — |
| 自由现金流率自由现金流/营收 | 290.5% | — |
| 资本支出强度资本支出/营收 | 13.2% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CLLSLSF
| Q4 25 | — | $68.4K | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | — | $-2.8M | ||
| Q1 25 | — | $-1.3M | ||
| Q4 24 | — | $339.2K | ||
| Q3 24 | — | $305.8K | ||
| Q2 24 | $28.9M | $642.7K | ||
| Q1 24 | — | $-422.3K |
自由现金流CLLSLSF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $27.6M | — | ||
| Q1 24 | — | — |
自由现金流率CLLSLSF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 290.5% | — | ||
| Q1 24 | — | — |
资本支出强度CLLSLSF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 13.2% | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLLS
暂无分部数据
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
